JF

19

Jun2015

QUEBEC: INESSS Upcoming Meetings with Manufacturers – February 2016 “Liste des médicaments”

INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the February 2016 “Liste des médicaments". These meetings will be held between August 28 and September 11, 2015, inclusively. Meetings will cover the following: Discussion on clinical studies Discussion ... Read More

12

Jun2015

QUÉBEC – INESSS Submission Deadlines: 2015-2016

The Minister of Health and Social Services has authorized three updates to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2016: February 1, June 1 and October 3, 2016. Updates to the lists of medications for multisource generic ... Read More

27

May2015

BC: Updates to BC Drug Review Process and Submission Requirements

The BC Ministry of Health recently wrote to manufacturers to communicate updates to its drug review process and reimbursement submission requirements. Updates to the Drug Review Process include: The Drug Benefit Council (DBC) will now screen drug submissions under review by CDR to determine if a full DBC review is necessary. If ... Read More

27

May2015

ON: Amendments to Ontario Regulation 201/96

The Ontario Public Drug Programs Division (OPDP) recently announced amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act. The amendments include the establishment of a pricing framework for certain generic products approved for listing on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index on or after April ... Read More

25

May2015

Canadian Organization for Rare Disorders (CORD) to release first ever Rare Disease Strategy

The Canadian Organization for Rare Disorders (CORD) announced Friday that it will help launch Canada's first ever Rare Disease Strategy on Monday, May 25th, at 10am in Ottawa on Parliament Hill. This Strategy was prepared by CORD further to extensive consultations over the past year with various stakeholders, with input from patients, ... Read More

10

Apr2015

WIB-Greater Montreal and the Technoparc Montréal Present a Conference on Drug Reimbursement in Quebec

PDCI Presentation at Women In Bio (Montreal Chapter) – April 16th, 2015 The Greater Montreal Chapter of Women In Bio will present a half-day conference followed by a keynote lunch on the latest developments and trends affecting market access ... Read More

10

Apr2015

Updates to the Manufacturer Submission Requirements in the Alberta Drug Benefit List (ADBL)

Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca For more information, please see ... Read More

07

Apr2015

CADTH: Guidelines for Manufacturers on pCODR Application Fees Implemented

CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month. Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation. For ... Read More

30

Mar2015

Rare Diseases Campaign

We recently participated in Mediaplanet Canada’s Rare Diseases campaign in which many industry leaders united to provide Canadians with a comprehensive view of Canada’s healthcare system and the policies that affect the lives of those living with or affected by rare disorders. The campaign was distributed through the National Post on ... Read More

25

Mar2015

The pan-Canadian Oncology Drug Review (pCODR) is moving

Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto. Please note the new main telephone and fax ... Read More